确定未折叠蛋白质反应途径作为胰腺癌中放射敏感化点
Jana Kern1, Daniela Schilling2, Christian Schneeweis3
1Department of Radiation Oncology, School of Medicine, Klinikum rechts der Isar, Technical University Munich (TUM), Munich, Germany.
概括
针对未折叠的蛋白质反应 (UPR) 可以克服胰腺管道腺癌 (PDAC) 的放射电阻. 用KIRA8或Ceapin-A7抑制UPR通路通过增加PDAC细胞的细胞亡和细胞循环停止来增强放射治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 辐射疗法 辐射疗法
背景情况:
- 胰腺管道腺癌 (PDAC) 呈现出显著的放射电阻,将放射治疗 (RT) 的有效性限制在约30%的患者中.
- 确定新的治疗点对于提高PDAC治疗中的RT疗效至关重要.
研究的目的:
- 确定可以提高胰腺管道腺癌放射疗法的疗效的分子标.
- 为了研究未折叠蛋白质响应 (UPR) 在PDAC放射电阻中的作用.
主要方法:
- 评估了38个小鼠PDAC细胞系的放射反应,使用了增殖和殖民地形成试验.
- 利用基因组丰富分析来识别差异表达的途径.
- 研究了将UPR抑制剂 (KIRA8用于IRE1α,Ceapin-A7用于ATF6) 与辐射结合使用细胞周期分布,DNA损伤分析 (γH2AX) 和亡试验的效果.
主要成果:
- 展开的蛋白质响应 (UPR) 途径在耐辐射的PDAC细胞系中得到高度表达.
- 用UPR抑制剂 (KIRA8或Ceapin-A7) 和辐射进行的联合治疗在耐辐射细胞系中显示出放射敏感化作用.
- 从机理上讲,KIRA8加辐射增加了亡,而Ceapin-A7加辐射诱导了放射抵抗性PDAC细胞中的G1细胞周期停止.
结论:
- 展开的蛋白质反应 (UPR) 涉及到PDAC的放射电阻.
- 抑制UPR通过增加亡和G1细胞周期停止来增强辐射敏感性.
- 这些发现支持开发针对UPR的组合疗法,以克服PDAC放射电阻.
相关概念视频
01:31Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
01:37The Unfolded Protein Response
4.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K